FAPI-4 is a substituted pyrrolidinyloxoethyl quinolinecarboxamides and one type of theranostic ligand for fibroblast activation protein (FAP). FAPI-4 is a FAP inhibitor (FAPI) and has been studied for its pharmaceutical properties in the diagnose or treatment of diseases driven by the overexpression of FAPs.